Modified-release hydrocortisone (Plenadren) launched for adrenal insufficiency

Plenadren (hydrocortisone) is indicated for maintenance therapy in adrenal insufficiency.

Modified-release hydrocortisone is not associated with the non-physiological cortisol peaks produced by standard glucocorticoid therapy.
Modified-release hydrocortisone is not associated with the non-physiological cortisol peaks produced by standard glucocorticoid therapy.

Plenadren (hydrocortisone) is a modified-release hydrocortisone tablet given once daily. It is intended to better mimic the physiological pattern of cortisol production than standard glucocorticoid replacement therapy.

Cortisol exposure

In a randomised open-label 12-week crossover study in 64 patients with primary adrenal insufficiency, once-daily modified-release hydrocortisone resulted in increased cortisol exposure during the first four hours after intake in the morning, with reduced exposure in the late afternoon and evening and over the 24-hour period compared with standard-release hydrocortisone (given three times daily). The safety profile was similar to that of conventional hydrocortisone.

View Plenadren drug record
 
Further information: ViroPharma

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

FemSeven Conti back in stock

FemSeven Conti back in stock

FemSeven Conti (estradiol/levonorgestrel) HRT patches...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Trial of interferon beta in COVID-19 patients begins in UK

Trial of interferon beta in COVID-19 patients begins in UK

A global phase III clinical trial to evaluate an inhaled...